Liver cancer
Conditions
Interventions
Sponsors
Department of Surgery, The University of Hong Kong
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years at the time of screening; 2.Diagnosis of HCC; 3.Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 4. With or without prior locoregional therapy such as transarterial chemoembolisation (TACE), radiofrequency ablation (RFA), and stereotactic body radiation therapy (SBRT) before surgery; 5.Meet any item indicating higher risk of tumour recurrence: any tumour size >= 5cm, number of tumour >= 3, presence of microvascular or marcovascular invasion, or poor tumour differentiation; 6.No prior systemic therapy for HCC; 7. No other active malignancies within 5 years, except malignancies with a negligible risk of metastasis or death (eg. 5-year overall survival rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer; 8. Willing and able to provide written informed consent for the collection and usage of biological samples.
Exclusion criteria
Exclusion criteria: 1.Non-HCC diagnosis, including fibrolamellar HCC, sarcomatoid HCC, mixed HCC cholangiocarcinoma etc; 2.Fail to give consent or refusal to take part in the study; 3.Child-Pugh class C liver cirrhosis; 4.Receipt of any prior systemic therapy for HCC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of Live-in-Cube in guiding the selection of optimal adjuvant treatment;Recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactAlbert Chan
Department of Surgery, The University of Hong Kong
Outcome results
None listed